Johns Hopkins University

Mso Pharma LLC

Richard J Traystman

Solomon H Snyder

Ted M Dawson

Valina L Dawson

Saul W Brusilow

Raymond C Koehler

Jun Bao

Mikael J Eliasson

Patricia D Hurn

Andrew Pieper

Kenji Sampei

Allen S Mandir

Methods for the treatment of both diseases susceptible to the inhibition of mammalian glutamine synthetase and progressive hyperammonemic encephalopathy comprising administering L-methionine S-sulfoxime at a dose not to exceed 10 mg/kg body weight are disclosed. Preferably, the dose should not exceed 8 mg/kg; more preferably, the dose should not exceed 5 mg/kg; most preferably, the dose should not exceed 2.5 mg/kg.

Dosage form of L-Methionine S-Sulfoximine

Neutral tissue damage resulting for ischemia and reperfusion injury or neurodegenerative diseases can be prevented by administering therapeutically effective amounts of certain selective inhibitors of poly(ADP-ribose)polymerase. The inhibitors can be administered intravenously, intraperitoneally, intramuscularly, intraventricularly, or orally. They can be administered as a capsule or tablet containing single or divided dose. Alternatively, the inhibitors can be administered as a sterile solution, suspension or emulsion.

Method of using selective parp inhibitors to prevent or treat neurotoxicity

Growing community of inventors

Ruxton, MD, United States of America

Richard J Traystman